about
MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiationAnuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxinThrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitorsA new path to leukemia with WITCharacterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis.Increased inflammation in lysozyme M-deficient mice in response to Micrococcus luteus and its peptidoglycanMafB deficiency causes defective respiratory rhythmogenesis and fatal central apnea at birthComparison of the microbicidal and muramidase activities of mouse lysozyme M and PA novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis.Induced pluripotent stem cell-derived human platelets: one step closer to the clinicEarly reversible induction of leukotriene synthesis in chicken myelomonocytic cells transformed by a temperature-sensitive mutant of avian leukemia virus E26.Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1.Stepwise reprogramming of B cells into macrophages.Forcing cells to change lineages.C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells.Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice.Musashi 2 in hematopoiesis.C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity.Reversibility of differentiation and proliferative capacity in avian myelomonocytic cells transformed by tsE26 leukemia virus.Differentiation plasticity of hematopoietic cells.Making eosinophils through subtle shifts in transcription factor expression.HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages.PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cellsA robust and highly efficient immune cell reprogramming system.Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitorsDistinct C/EBP functions are required for eosinophil lineage commitment and maturationCCAAT/enhancer binding protein alpha (C/EBP(alpha))-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation.Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signalingC/EBPα Activates Pre-existing and De Novo Macrophage Enhancers during Induced Pre-B Cell Transdifferentiation and MyelopoiesisRecovery of myc-specific sequences by a partially transformation-defective mutant of avian myelocytomatosis virus, MC29, correlates with the restoration of transforming activityMyb: a transcriptional activator linking proliferation and differentiation in hematopoietic cells.PU.1 is not strictly required for B cell development and its absence induces a B-2 to B-1 cell switchMutant of avian erythroblastosis virus defective for erythroblast transformation: deletion in the erb portion of p75 suggests function of the protein in leukemogenesisDeterminants of lymphoid-myeloid lineage diversification.Tissue-specific control of brain-enriched miR-7 biogenesisEarly decisions in lymphoid development.Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells.Heterogeneity of embryonic and adult stem cells.Avian leukemia viruses: interaction with their target cells in vivo and in vitro.Transcription factor-induced enhancer modulations during cell fate conversions.
P50
Q24336558-FE58E5D1-9F1D-4D52-B1AB-6E7E578A512BQ24675668-8B3018E2-4241-4EC0-94B6-D3B98539AE4EQ24683778-2D1FB7C4-8413-4EE8-8825-B23F95D2E7BAQ28257463-CB6C5DA8-4621-4D85-BCDE-5161D912769EQ28505080-56EDE7D0-C1C0-4B64-A124-98AE023FED43Q28511228-67B3ADCC-283F-4981-A5C0-949561B35E79Q28585927-29DCEC71-911B-4916-ACEA-EA2F8A5933E2Q28589072-595B66B9-E433-480F-A7B0-1BD1A858E0A0Q30528487-5CFCC88C-D5CF-4F2D-A1CD-77EDD961F9C2Q33393364-1976CBB0-6F57-439B-A39F-DA8689DCDEB3Q33834893-66174A53-A346-4037-8FB3-923E4E32002CQ33889041-0D1E5101-1051-45A1-A4DE-18B6CBE57C0DQ33978638-E7DBA352-84B8-43B4-8425-6DE5F4381992Q34020397-64301E1E-3375-461B-8C1A-A906B94F43EEQ34039326-AA9CA192-51C6-494F-961B-88D32AC4AA6BQ34187328-A0D5FB14-A8ED-420B-B33C-D65207A87107Q34269582-D9249E2C-0315-4ADE-ADF7-0E34E378E60AQ34336350-9A881C83-98F3-4CD2-AF1B-AD7005F5B7F8Q34552230-32FCEE20-FFFD-41F1-8700-285951D94435Q34607310-06066F46-F8AF-4B80-8800-D778EF38BE7DQ34667489-395AE0D2-7E08-4655-B40B-40656D6D8BD2Q34733627-2EC10496-D4DE-440B-8CBE-A0A9EECD884DQ34771857-C4DF6A58-94D0-451A-B172-3E9E444C6356Q35011707-62842C41-9301-4570-8435-C7E2A0A88DBCQ35204890-955320B0-9191-4289-98DF-14203A364B58Q35206830-677F49E3-3B68-4BE3-8E6E-56CA4AE160A7Q35345851-E5A3D9AD-ACA9-4B6A-82E4-EC33C04C9678Q35883118-B84F4E0C-C677-4B4C-9691-E0587838F666Q36201595-0B3E6361-D776-4B79-A3E2-7BA35CF87A66Q36320451-A1D50758-E6E6-45DF-9575-075EA93D8A26Q36354824-361678CF-BE36-45BB-AE48-C0385FF06955Q36403113-56A0BE09-6C18-461B-92EC-83B312AA7005Q36415847-36372049-0CED-48AE-85FB-C69F877F7E4CQ36427387-2A85E9AC-0B5B-4BCC-AE61-A6F02540429BQ36557067-92B5D575-5CCB-4463-B975-C162E3821FB5Q36738371-82B88C40-6CF7-4002-86E8-439B0D6ED026Q36886768-4928C4AA-3E8A-471D-8DCD-C20F68E07E00Q37317339-735C3AC7-1336-45C4-AE1C-3563FC89D1B7Q37869111-C58493D9-FA10-419A-A69E-8F1897FE3C84Q38130771-88EFE2C2-249E-4161-A760-D2742C353FE9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Graf
@ast
Thomas Graf
@da
Thomas Graf
@de
Thomas Graf
@en
Thomas Graf
@es
Thomas Graf
@nl
Thomas Graf
@sl
type
label
Thomas Graf
@ast
Thomas Graf
@da
Thomas Graf
@de
Thomas Graf
@en
Thomas Graf
@es
Thomas Graf
@nl
Thomas Graf
@sl
altLabel
Graf T
@en
Thomas Graf Graf T, Graf Thomas
@en
prefLabel
Thomas Graf
@ast
Thomas Graf
@da
Thomas Graf
@de
Thomas Graf
@en
Thomas Graf
@es
Thomas Graf
@nl
Thomas Graf
@sl
P1053
B-4252-2015
P106
P1153
16502965900
P21
P31
P3829
P496
0000-0003-2774-4117